{
  "nct_id": "NCT06252649",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "curated_on": "2024-02-12",
  "study_start_date": "2024-07-17",
  "study_completion_date": "",
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Drug: Panitumumab"
      },
      {
        "drug_name": "Drug: Bevacizumab-awwb"
      },
      {
        "drug_name": "Drug: Sotorasib"
      },
      {
        "drug_name": "Drug: FOLFIRI Regimen"
      }
    ]
  },
  "long_title": "Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",
  "last_updated": "2025-08-29",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "Group1"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "PHASE3",
  "principal_investigator": "NA",
  "principal_investigator_institution": "Amgen",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program1"
      }
    ]
  },
  "protocol_id": 0,
  "protocol_ids": [],
  "protocol_no": "",
  "protocol_target_accrual": 450,
  "protocol_type": "INTERVENTIONAL",
  "prior_treatment_requirements": [
    "Inclusion Criteria:",
    "* Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.",
    "* Central laboratory detection of KRAS p.G12C mutation.",
    "* Measurable metastatic disease per RECIST v1.1 criteria.",
    "* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.",
    "* Adequate organ function.",
    "Exclude - Exclusion Criteria:",
    "Exclude - * Active, untreated brain metastases.",
    "Exclude - * Leptomeningeal disease",
    "Exclude - * Previous treatment with a KRAS p.G12C inhibitor",
    "Exclude - * History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan"
  ],
  "short_title": "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": [
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "Amgen",
        "sponsor_protocol_no": "",
        "sponsor_roles": "sponsor"
      }
    ]
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.",
  "treatment_list": {
    "step": [
      {
        "step_internal_id": 111,
        "step_code": "1",
        "step_type": "Registration",
        "arm": [
          {
            "arm_code": "Arm A: Sotorasib + Panitumumab + FOLFIRI",
            "arm_internal_id": 0,
            "arm_description": "Sotorasib will be taken daily (QD) as an oral tablet. Panitumumab and FOLFIRI will be received every 2 weeks (Q2W) via intravenous (IV) infusion.",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: FOLFIRI Regimen",
                "level_internal_id": 0,
                "level_suspended": "N"
              },
              {
                "level_code": "1",
                "level_description": "Drug: Sotorasib",
                "level_internal_id": 1,
                "level_suspended": "N"
              },
              {
                "level_code": "2",
                "level_description": "Drug: Panitumumab",
                "level_internal_id": 2,
                "level_suspended": "N"
              }
            ]
          },
          {
            "arm_code": "Arm B: FOLFIRI with or Without Bevacizumab-awwb",
            "arm_internal_id": 1,
            "arm_description": "Participants will receive FOLFIRI Q2W with or without bevacizumab-awwb.",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: FOLFIRI Regimen",
                "level_internal_id": 0,
                "level_suspended": "N"
              },
              {
                "level_code": "1",
                "level_description": "Drug: Bevacizumab-awwb",
                "level_internal_id": 1,
                "level_suspended": "N"
              }
            ]
          }
        ],
        "match": [
          {
            "and": [
              {
                "clinical": {
                  "age_numerical": ">=18",
                  "disease_status": [
                    "Metastatic"
                  ],
                  "oncotree_primary_diagnosis": "Colorectal Adenocarcinoma"
                }
              },
              {
                "or": [
                  {
                    "genomic": {
                      "hugo_symbol": "KRAS",
                      "variant_category": "Mutation"
                    }
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  }
}